Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Communication
  • Published:

Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer

Abstract

Survivin, a member of the inhibitory apoptosis protein family, gives rise, by an alternative splicing, to four variants with different functions. Many experimental studies indicate that p53 can regulate the expression of survivin and some of its splice variants. Although both the expression of survivin splice variants and the p53 gene were frequently altered in human cancers, nothing is known about their interactions in in vivo tumour samples. Here, we report that, in 162 breast carcinomas, p53 mutations are significantly associated with an increased expression of survivin and, in particular, its antiapoptotic splice variants (survivin-ΔEx3 and survivin-3B). The upregulation of these variant expressions is particularly related to p53 mutations occurring in the residues belonging to the tetramerization domain. The loss of heterozygosity in the p53 gene is also associated with an increased expression of the survivin-ΔEx3 variant. The expression of the proapoptotic variants (survivin-2B and survivin-2α) is not affected by any of these alterations. Our results provide for the first time in vivo evidence that, in human breast cancer, the survivin expression as well as its splicing depends on the p53 status. The results also suggest that the upregulation of antiapoptotic survivin variant expression by the mutant p53 may increase breast cancer cells survival and resistance to therapy.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Altieri DC . (2003). Nat Rev Cancer 3: 46–54.

  • Ambrosini G, Adida C, Altieri DC . (1997). Nat Med 3: 917–921.

  • Ambrosini G, Adida C, Sirugo G, Altieiri DC . (1998). J Biol Chem 273: 11177–11182.

  • Badran A, Yoshida A, Ishikawa K, Goi T, Yamagushi A, Ueda T et al. (2004). Biochem Biophys Res Commun 314: 902–907.

  • Bullok AN, Fersht AR . (2001). Nat Rev Cancer 1: 68–76.

  • Caldas H, Honsey LE, Altura RA . (2005). Mol Cancer 4: 11–20.

  • Cawkwell L, Lewis FA, Quirke T . (1994). Br J Cancer 70: 813–818.

  • Cho Y, Gorina S, Jeffrey PD, Pavletich NP . (1994). Science 265: 336–355.

  • Dumont P, Leu JI, Della Pietra III AC, George DL, Murphy M . (2003). Nat Genet 33: 357–365.

  • Estève PO, Chin HG, Pradhan S . (2005). Proc Natl Acad Sci USA 102: 1000–1005.

  • Franco N, Arnould L, Mege F, Picard SF, Arveux P, Lizard-Nacol S . (2003). Arch Surg 138: 291–295.

  • Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M . (2002). J Biol Chem 277: 3247–3257.

  • Livak KJ, Schmittgen TD . (2001). Methods 25: 402–408.

  • Lohr K, Moritz C, Contente A, Dobbelstein M . (2003). J Biol Chem 278: 32507–32516.

  • Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD . (1999). Cancer Res 59: 6097–6102.

  • Maxwell SA, Acosta SA, Davis GE . (1999). Apoptosis 4: 109–114.

  • Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S et al. (2002). Oncogene 21: 2613–2622.

  • Moyret-Lalle C, Duriez C, Kerckhove JV, Gilbert C, Wang Q, Puisieux A . (2001). Cancer Res 61: 486–488.

  • Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ et al. (1999). Genes and Dev 13: 2490–2501.

  • Nasu S, Yagihashi A, Izawa A, Saito K, Asanuna K, Nakamura M et al. (2002). Anticancer Res 22: 2613–2622.

  • O'Driscoll L, Linehan R, Kennedy SM, Cronin D, Purcell R, Glynn S et al. (2003). Cancer Lett 201: 225–236.

  • Punga T, Akusjarvi G . (2003). FEBS Lett 552: 214–218.

  • Ryan B, O'Donovan N, Browne B, O'Shea C, Crown J, Hill ADK et al. (2005). Br J Cancer 92: 120–124.

  • Sommer KW, Schamberger CJ, Schmidt GE, Sasgary S, Cerni C . (2003). Oncogene 22: 4266–4280.

  • Soussi T, Beroud C . (2001). Nat Rev Cancer 1: 233–240.

  • Tran J, Master Z, Yu J, Rak J, Dumont D, Kerbel R . (2002). Proc Natl Acad Sci USA 99: 4349–4354.

  • Tsuji N, Furuse K, Asanuma K, Furuya M, Kondoh K, Kamagata C et al. (2004). Breast Cancer Res Treat 87: 23–31.

  • van Oijen GCT, Slootweg PJ . (2000). Clin Cancer Res 6: 2138–2145.

  • Végran F, Boidot R, Oudin C, Riedinger JM, Lizard-Nacol S . (2005). Int J Oncol 27: 1151–1157.

  • Xu M, el-Gewely MR . (2003). Oncol Res 13: 429–436.

  • Yoon H, Liyanarachci S, Wright FA, Davaluri R, Lockman JC, de la Chapelle A et al. (2002). Proc Natl Acad Sci USA 99: 15632–15637.

  • Zhou X, Wang XW, Xu L, Hagiwara K, Ngashima M, Wolkowicz R et al. (1999). Cancer Res 59: 843–848.

  • Zhu N, Gu L, Findley HW, Li F, Zhou M . (2004). Oncogene 23: 7545–7551.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S Lizard-Nacol.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Végran, F., Boidot, R., Oudin, C. et al. Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer. Oncogene 26, 290–297 (2007). https://doi.org/10.1038/sj.onc.1209784

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209784

Keywords

This article is cited by

Search

Quick links